Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cost-Benefit Analysis | 32 | 2023 | 5388 | 2.620 |
Why?
|
Cardiovascular Diseases | 41 | 2024 | 15142 | 2.550 |
Why?
|
Drug Costs | 11 | 2023 | 1105 | 2.410 |
Why?
|
Amyloid Neuropathies, Familial | 3 | 2023 | 136 | 1.960 |
Why?
|
Hypercholesterolemia | 9 | 2024 | 1151 | 1.940 |
Why?
|
Hypolipidemic Agents | 5 | 2023 | 606 | 1.890 |
Why?
|
Anticholesteremic Agents | 6 | 2019 | 979 | 1.560 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 11 | 2023 | 3255 | 1.550 |
Why?
|
Endocarditis | 5 | 2022 | 349 | 1.400 |
Why?
|
Primary Prevention | 8 | 2023 | 1167 | 1.400 |
Why?
|
Health Expenditures | 10 | 2023 | 2348 | 1.220 |
Why?
|
Proprotein Convertases | 3 | 2016 | 95 | 1.200 |
Why?
|
Heart Failure | 16 | 2023 | 10896 | 1.180 |
Why?
|
Phenprocoumon | 2 | 2015 | 19 | 1.020 |
Why?
|
Acenocoumarol | 2 | 2015 | 18 | 1.020 |
Why?
|
Hyperlipoproteinemia Type II | 5 | 2024 | 375 | 1.000 |
Why?
|
Quality-Adjusted Life Years | 12 | 2022 | 1683 | 0.990 |
Why?
|
Dyslipidemias | 2 | 2023 | 851 | 0.950 |
Why?
|
Medicare | 23 | 2023 | 6565 | 0.950 |
Why?
|
Specialty Boards | 2 | 2016 | 227 | 0.940 |
Why?
|
Inflation, Economic | 1 | 2023 | 28 | 0.940 |
Why?
|
Acute Coronary Syndrome | 6 | 2021 | 2337 | 0.920 |
Why?
|
Benzoxazoles | 2 | 2020 | 79 | 0.860 |
Why?
|
Antihypertensive Agents | 7 | 2021 | 2047 | 0.840 |
Why?
|
Ticlopidine | 4 | 2015 | 899 | 0.830 |
Why?
|
Cholesterol, LDL | 9 | 2024 | 2354 | 0.820 |
Why?
|
Atherosclerosis | 8 | 2024 | 3445 | 0.800 |
Why?
|
Hypertension | 11 | 2024 | 8480 | 0.800 |
Why?
|
Endocarditis, Bacterial | 2 | 2022 | 455 | 0.780 |
Why?
|
American Heart Association | 15 | 2024 | 1057 | 0.760 |
Why?
|
United States | 66 | 2024 | 69859 | 0.760 |
Why?
|
Aortic Valve Stenosis | 7 | 2023 | 1955 | 0.730 |
Why?
|
Vital Signs | 1 | 2021 | 142 | 0.720 |
Why?
|
Costs and Cost Analysis | 2 | 2016 | 1680 | 0.710 |
Why?
|
Diabetes Mellitus | 7 | 2024 | 5752 | 0.690 |
Why?
|
Coronary Disease | 11 | 2024 | 6078 | 0.670 |
Why?
|
Pericarditis | 1 | 2020 | 128 | 0.660 |
Why?
|
Humans | 158 | 2024 | 743811 | 0.650 |
Why?
|
Internal Medicine | 2 | 2016 | 1009 | 0.650 |
Why?
|
Platelet Aggregation Inhibitors | 4 | 2015 | 3070 | 0.650 |
Why?
|
Cardiomyopathies | 2 | 2020 | 1911 | 0.630 |
Why?
|
Blood Pressure | 8 | 2021 | 8551 | 0.610 |
Why?
|
Glucosides | 1 | 2021 | 451 | 0.600 |
Why?
|
Postoperative Hemorrhage | 3 | 2023 | 409 | 0.590 |
Why?
|
Ownership | 1 | 2019 | 332 | 0.580 |
Why?
|
Warfarin | 3 | 2021 | 1497 | 0.570 |
Why?
|
Atrial Fibrillation | 6 | 2023 | 5033 | 0.550 |
Why?
|
Stroke Volume | 5 | 2023 | 5002 | 0.540 |
Why?
|
Health Services | 1 | 2021 | 758 | 0.540 |
Why?
|
Medicare Part D | 4 | 2023 | 328 | 0.530 |
Why?
|
Ventricular Dysfunction, Left | 2 | 2023 | 2074 | 0.530 |
Why?
|
Policy Making | 1 | 2019 | 554 | 0.530 |
Why?
|
Computers, Handheld | 1 | 2017 | 208 | 0.520 |
Why?
|
Health Status Disparities | 3 | 2021 | 1796 | 0.510 |
Why?
|
Benzhydryl Compounds | 1 | 2021 | 844 | 0.510 |
Why?
|
Cardiovascular Agents | 1 | 2021 | 850 | 0.510 |
Why?
|
Coronary Artery Bypass | 6 | 2022 | 2288 | 0.500 |
Why?
|
Secondary Prevention | 6 | 2024 | 1529 | 0.500 |
Why?
|
Antibodies, Monoclonal | 5 | 2017 | 9272 | 0.500 |
Why?
|
Protease Inhibitors | 1 | 2018 | 792 | 0.470 |
Why?
|
Anti-Bacterial Agents | 3 | 2023 | 7172 | 0.470 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2023 | 9944 | 0.470 |
Why?
|
Anticoagulants | 6 | 2023 | 4599 | 0.470 |
Why?
|
Adenosine | 2 | 2015 | 825 | 0.440 |
Why?
|
Coronary Artery Disease | 8 | 2024 | 6485 | 0.420 |
Why?
|
Defibrillators, Implantable | 1 | 2022 | 1439 | 0.420 |
Why?
|
Genotype | 4 | 2023 | 12944 | 0.420 |
Why?
|
Influenza, Human | 1 | 2023 | 1480 | 0.410 |
Why?
|
Angina Pectoris | 2 | 2016 | 977 | 0.410 |
Why?
|
Heart Valve Prosthesis Implantation | 4 | 2023 | 1537 | 0.410 |
Why?
|
Public Facilities | 1 | 2011 | 34 | 0.400 |
Why?
|
Respiratory Insufficiency | 1 | 2020 | 1199 | 0.400 |
Why?
|
Cardiology | 4 | 2023 | 1668 | 0.390 |
Why?
|
Aged | 45 | 2023 | 163178 | 0.380 |
Why?
|
Mass Screening | 3 | 2023 | 5251 | 0.380 |
Why?
|
Cost Sharing | 3 | 2020 | 407 | 0.370 |
Why?
|
Cardiovascular System | 1 | 2018 | 828 | 0.370 |
Why?
|
Drug Therapy, Combination | 6 | 2023 | 6487 | 0.370 |
Why?
|
Heart Diseases | 4 | 2024 | 2789 | 0.350 |
Why?
|
Nutrition Surveys | 5 | 2023 | 1660 | 0.350 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2008 | 1516 | 0.350 |
Why?
|
Health Services Accessibility | 3 | 2023 | 5136 | 0.340 |
Why?
|
Medical Oncology | 1 | 2021 | 2267 | 0.340 |
Why?
|
Risk Assessment | 6 | 2023 | 23327 | 0.340 |
Why?
|
Rheumatic Heart Disease | 2 | 2020 | 177 | 0.340 |
Why?
|
HIV Infections | 7 | 2021 | 16715 | 0.320 |
Why?
|
Comparative Effectiveness Research | 2 | 2013 | 680 | 0.320 |
Why?
|
Cost of Illness | 2 | 2020 | 1859 | 0.310 |
Why?
|
Hemorrhage | 4 | 2023 | 3458 | 0.310 |
Why?
|
Insulin | 1 | 2022 | 6584 | 0.310 |
Why?
|
Health Care Costs | 6 | 2021 | 3207 | 0.310 |
Why?
|
Patient Readmission | 5 | 2023 | 3117 | 0.300 |
Why?
|
Stroke | 8 | 2024 | 9975 | 0.300 |
Why?
|
Medical Informatics | 1 | 2015 | 745 | 0.300 |
Why?
|
Population Surveillance | 2 | 2017 | 2614 | 0.300 |
Why?
|
Anti-HIV Agents | 2 | 2021 | 4255 | 0.300 |
Why?
|
Artifacts | 1 | 2016 | 1904 | 0.300 |
Why?
|
Patient Care Planning | 1 | 2013 | 915 | 0.290 |
Why?
|
Myocardial Ischemia | 3 | 2023 | 2150 | 0.290 |
Why?
|
Male | 62 | 2024 | 349776 | 0.290 |
Why?
|
Telemedicine | 4 | 2021 | 2874 | 0.290 |
Why?
|
Myocardial Infarction | 7 | 2022 | 11708 | 0.290 |
Why?
|
India | 5 | 2020 | 2200 | 0.290 |
Why?
|
Mortality | 4 | 2021 | 2862 | 0.290 |
Why?
|
Female | 64 | 2024 | 380020 | 0.280 |
Why?
|
Aspirin | 4 | 2023 | 3283 | 0.280 |
Why?
|
Developed Countries | 2 | 2024 | 437 | 0.280 |
Why?
|
Crowding | 2 | 2017 | 145 | 0.270 |
Why?
|
Adult | 37 | 2024 | 213889 | 0.260 |
Why?
|
Drug Combinations | 3 | 2019 | 1958 | 0.260 |
Why?
|
Treatment Outcome | 20 | 2023 | 63042 | 0.250 |
Why?
|
Barbering | 2 | 2021 | 9 | 0.250 |
Why?
|
Algorithms | 3 | 2022 | 13869 | 0.250 |
Why?
|
Angioplasty, Balloon, Coronary | 1 | 2012 | 1874 | 0.240 |
Why?
|
Registries | 7 | 2022 | 8090 | 0.240 |
Why?
|
Fatty Acids | 2 | 2023 | 1809 | 0.240 |
Why?
|
Middle Aged | 43 | 2024 | 213241 | 0.240 |
Why?
|
Risk Factors | 25 | 2024 | 72252 | 0.240 |
Why?
|
Thiazolidinediones | 1 | 2007 | 475 | 0.240 |
Why?
|
Aged, 80 and over | 21 | 2022 | 57744 | 0.230 |
Why?
|
Income | 2 | 2024 | 1913 | 0.230 |
Why?
|
Decision Support Techniques | 4 | 2019 | 1956 | 0.220 |
Why?
|
Tetrazoles | 2 | 2019 | 834 | 0.220 |
Why?
|
Minority Groups | 4 | 2024 | 1222 | 0.220 |
Why?
|
Lipids | 3 | 2023 | 3307 | 0.220 |
Why?
|
Aftercare | 3 | 2023 | 870 | 0.220 |
Why?
|
Serine Endopeptidases | 3 | 2016 | 1073 | 0.220 |
Why?
|
Delivery of Health Care | 3 | 2017 | 5319 | 0.210 |
Why?
|
Pharmacists | 2 | 2021 | 248 | 0.210 |
Why?
|
Aortic Valve | 5 | 2023 | 1920 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3134 | 0.210 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3241 | 0.210 |
Why?
|
Angina, Unstable | 2 | 2019 | 926 | 0.210 |
Why?
|
Hypoglycemic Agents | 2 | 2020 | 2877 | 0.200 |
Why?
|
Practice Guidelines as Topic | 7 | 2021 | 7270 | 0.200 |
Why?
|
Healthcare Disparities | 3 | 2022 | 3155 | 0.200 |
Why?
|
Viridans Streptococci | 1 | 2021 | 15 | 0.200 |
Why?
|
Substance-Related Disorders | 3 | 2023 | 4254 | 0.200 |
Why?
|
Rehabilitation Centers | 1 | 2023 | 253 | 0.200 |
Why?
|
Dicarboxylic Acids | 1 | 2021 | 69 | 0.200 |
Why?
|
Subtilisins | 1 | 2021 | 83 | 0.190 |
Why?
|
Disasters | 1 | 2006 | 511 | 0.180 |
Why?
|
Disaster Planning | 1 | 2006 | 548 | 0.180 |
Why?
|
Cohort Studies | 11 | 2024 | 40545 | 0.180 |
Why?
|
Electronics | 1 | 2022 | 321 | 0.180 |
Why?
|
Hospitals, Rural | 1 | 2022 | 172 | 0.180 |
Why?
|
Antibiotic Prophylaxis | 2 | 2022 | 638 | 0.180 |
Why?
|
Computer Simulation | 3 | 2019 | 6188 | 0.180 |
Why?
|
Cocaine-Related Disorders | 1 | 2023 | 460 | 0.180 |
Why?
|
California | 3 | 2019 | 1402 | 0.180 |
Why?
|
Markov Chains | 2 | 2021 | 968 | 0.180 |
Why?
|
Dental Care | 1 | 2022 | 261 | 0.180 |
Why?
|
Hospitals, Urban | 1 | 2022 | 499 | 0.180 |
Why?
|
Housing | 2 | 2023 | 664 | 0.170 |
Why?
|
Catheter Ablation | 1 | 2013 | 2758 | 0.170 |
Why?
|
Rural Health | 1 | 2021 | 305 | 0.170 |
Why?
|
Quality of Life | 2 | 2020 | 12788 | 0.170 |
Why?
|
Marketing | 1 | 2021 | 212 | 0.170 |
Why?
|
Prealbumin | 1 | 2020 | 207 | 0.170 |
Why?
|
Tricuspid Valve Insufficiency | 1 | 2022 | 349 | 0.170 |
Why?
|
Budgets | 1 | 2020 | 229 | 0.160 |
Why?
|
Prisoners | 1 | 2022 | 297 | 0.160 |
Why?
|
Adrenergic beta-Antagonists | 2 | 2014 | 1240 | 0.160 |
Why?
|
Hyperlipidemias | 1 | 2023 | 789 | 0.160 |
Why?
|
Protective Devices | 1 | 2018 | 71 | 0.160 |
Why?
|
Prescriptions | 1 | 2021 | 387 | 0.160 |
Why?
|
Urban Health | 1 | 2021 | 547 | 0.160 |
Why?
|
Cholesterol, HDL | 1 | 2005 | 1813 | 0.160 |
Why?
|
Retrospective Studies | 19 | 2023 | 77410 | 0.160 |
Why?
|
Aerospace Medicine | 1 | 2018 | 84 | 0.160 |
Why?
|
Cocaine | 1 | 2023 | 1007 | 0.160 |
Why?
|
Nitroglycerin | 1 | 2019 | 325 | 0.150 |
Why?
|
Patient Discharge | 4 | 2023 | 3317 | 0.150 |
Why?
|
Holidays | 1 | 2017 | 42 | 0.150 |
Why?
|
Models, Statistical | 5 | 2020 | 5100 | 0.150 |
Why?
|
Economics, Medical | 1 | 2017 | 113 | 0.150 |
Why?
|
Common Cold | 1 | 2017 | 61 | 0.150 |
Why?
|
Mexico | 1 | 2019 | 689 | 0.150 |
Why?
|
Legislation, Drug | 1 | 2019 | 206 | 0.150 |
Why?
|
Hinduism | 1 | 2016 | 14 | 0.150 |
Why?
|
Biphenyl Compounds | 2 | 2019 | 913 | 0.150 |
Why?
|
Death, Sudden | 1 | 2018 | 302 | 0.140 |
Why?
|
State Government | 1 | 2019 | 372 | 0.140 |
Why?
|
Nigeria | 1 | 2019 | 733 | 0.140 |
Why?
|
Mucocutaneous Lymph Node Syndrome | 1 | 2021 | 546 | 0.140 |
Why?
|
Brain Ischemia | 2 | 2022 | 3264 | 0.140 |
Why?
|
Nebulizers and Vaporizers | 1 | 2017 | 139 | 0.140 |
Why?
|
Rural Population | 3 | 2022 | 2207 | 0.140 |
Why?
|
Shock, Cardiogenic | 1 | 2021 | 688 | 0.140 |
Why?
|
Troponin I | 1 | 2020 | 619 | 0.140 |
Why?
|
Pandemics | 5 | 2023 | 8385 | 0.140 |
Why?
|
Hospital Costs | 2 | 2020 | 985 | 0.140 |
Why?
|
Epidemics | 2 | 2019 | 523 | 0.140 |
Why?
|
United States Department of Veterans Affairs | 1 | 2020 | 875 | 0.140 |
Why?
|
Heart Valve Prosthesis | 2 | 2022 | 1489 | 0.130 |
Why?
|
Prescription Drugs | 1 | 2023 | 593 | 0.130 |
Why?
|
Thrombocytopenia | 1 | 2023 | 1178 | 0.130 |
Why?
|
Patient Acceptance of Health Care | 2 | 2019 | 3020 | 0.130 |
Why?
|
Adrenergic beta-Agonists | 1 | 2017 | 346 | 0.130 |
Why?
|
Follow-Up Studies | 9 | 2022 | 39001 | 0.130 |
Why?
|
Cause of Death | 4 | 2021 | 3580 | 0.130 |
Why?
|
Troponin T | 1 | 2020 | 754 | 0.130 |
Why?
|
Data Mining | 1 | 2020 | 537 | 0.130 |
Why?
|
Marijuana Abuse | 1 | 2019 | 403 | 0.130 |
Why?
|
Education, Medical, Continuing | 1 | 2020 | 840 | 0.130 |
Why?
|
Myocardial Revascularization | 1 | 2019 | 841 | 0.120 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 738 | 0.120 |
Why?
|
Hospital Mortality | 4 | 2022 | 5316 | 0.120 |
Why?
|
Medical Audit | 1 | 2016 | 466 | 0.120 |
Why?
|
Smoking | 1 | 2011 | 8984 | 0.120 |
Why?
|
Dogs | 1 | 2019 | 3911 | 0.120 |
Why?
|
Cross-Sectional Studies | 7 | 2024 | 25032 | 0.120 |
Why?
|
Neoplasms | 2 | 2021 | 21675 | 0.120 |
Why?
|
Public Health Practice | 1 | 2016 | 217 | 0.120 |
Why?
|
Reimbursement Mechanisms | 1 | 2020 | 670 | 0.120 |
Why?
|
Direct Service Costs | 1 | 2014 | 62 | 0.120 |
Why?
|
South Africa | 1 | 2019 | 1731 | 0.120 |
Why?
|
Employment | 1 | 2021 | 1132 | 0.120 |
Why?
|
Cerebrovascular Disorders | 1 | 2021 | 1504 | 0.120 |
Why?
|
Outpatients | 1 | 2022 | 1488 | 0.120 |
Why?
|
Drugs, Generic | 2 | 2021 | 421 | 0.120 |
Why?
|
Cough | 1 | 2017 | 555 | 0.120 |
Why?
|
Clinical Trials as Topic | 4 | 2021 | 7908 | 0.120 |
Why?
|
China | 1 | 2019 | 2243 | 0.110 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2019 | 923 | 0.110 |
Why?
|
Heart Rate | 2 | 2014 | 4091 | 0.110 |
Why?
|
Reminder Systems | 1 | 2016 | 371 | 0.110 |
Why?
|
Urinary Tract Infections | 1 | 2019 | 788 | 0.110 |
Why?
|
Bayes Theorem | 1 | 2021 | 2307 | 0.110 |
Why?
|
Patient Transfer | 1 | 2020 | 762 | 0.110 |
Why?
|
Mitral Valve Insufficiency | 1 | 2022 | 1421 | 0.110 |
Why?
|
Electrocardiography | 2 | 2020 | 6441 | 0.110 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2014 | 257 | 0.110 |
Why?
|
Medically Underserved Area | 1 | 2015 | 252 | 0.110 |
Why?
|
Prevalence | 5 | 2023 | 15211 | 0.110 |
Why?
|
Proliferating Cell Nuclear Antigen | 2 | 2023 | 286 | 0.110 |
Why?
|
Drug Administration Schedule | 3 | 2021 | 4931 | 0.110 |
Why?
|
Arthroplasty, Replacement, Knee | 1 | 2023 | 1458 | 0.110 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2021 | 1872 | 0.100 |
Why?
|
Walking | 1 | 2019 | 1182 | 0.100 |
Why?
|
Life Style | 3 | 2021 | 3833 | 0.100 |
Why?
|
RNA, Small Interfering | 1 | 2021 | 3504 | 0.100 |
Why?
|
Child Mortality | 1 | 2014 | 198 | 0.100 |
Why?
|
Medication Therapy Management | 1 | 2013 | 127 | 0.100 |
Why?
|
Uncertainty | 1 | 2016 | 735 | 0.100 |
Why?
|
Maternal Mortality | 1 | 2014 | 310 | 0.100 |
Why?
|
Social Class | 1 | 2020 | 1997 | 0.100 |
Why?
|
Health Services Needs and Demand | 2 | 2021 | 1411 | 0.100 |
Why?
|
Age Factors | 5 | 2020 | 18355 | 0.100 |
Why?
|
Venous Thromboembolism | 1 | 2023 | 1670 | 0.100 |
Why?
|
Insurance Coverage | 2 | 2019 | 1900 | 0.100 |
Why?
|
Pneumonia | 2 | 2019 | 2133 | 0.100 |
Why?
|
Drug Prescriptions | 2 | 2017 | 1636 | 0.090 |
Why?
|
Natural Language Processing | 1 | 2018 | 1041 | 0.090 |
Why?
|
Coronary Thrombosis | 1 | 2014 | 495 | 0.090 |
Why?
|
Tachycardia, Ectopic Atrial | 1 | 2010 | 66 | 0.090 |
Why?
|
Diarrhea | 1 | 2017 | 1348 | 0.090 |
Why?
|
Young Adult | 10 | 2024 | 56392 | 0.090 |
Why?
|
Fever | 1 | 2017 | 1616 | 0.090 |
Why?
|
Thrombosis | 1 | 2023 | 2968 | 0.090 |
Why?
|
Heart | 1 | 2023 | 4460 | 0.090 |
Why?
|
Quality Indicators, Health Care | 1 | 2020 | 1831 | 0.090 |
Why?
|
Hospitals | 1 | 2023 | 3953 | 0.090 |
Why?
|
Models, Cardiovascular | 1 | 2015 | 996 | 0.090 |
Why?
|
Medicaid | 2 | 2021 | 2736 | 0.090 |
Why?
|
Health Resources | 1 | 2016 | 912 | 0.090 |
Why?
|
Thiophenes | 1 | 2014 | 589 | 0.090 |
Why?
|
User-Computer Interface | 1 | 2016 | 1431 | 0.080 |
Why?
|
Infant Mortality | 1 | 2014 | 755 | 0.080 |
Why?
|
Cardiac Complexes, Premature | 1 | 2008 | 64 | 0.080 |
Why?
|
Stents | 1 | 2021 | 3280 | 0.080 |
Why?
|
World Health Organization | 1 | 2014 | 1317 | 0.080 |
Why?
|
Coronary Vessels | 1 | 2020 | 3106 | 0.080 |
Why?
|
Metabolic Diseases | 1 | 2015 | 658 | 0.080 |
Why?
|
Guidelines as Topic | 1 | 2015 | 1404 | 0.080 |
Why?
|
Heart Ventricles | 1 | 2020 | 3817 | 0.080 |
Why?
|
Coronary Angiography | 1 | 2020 | 4576 | 0.080 |
Why?
|
Ambulatory Care | 2 | 2016 | 2707 | 0.080 |
Why?
|
Incidence | 8 | 2021 | 20948 | 0.080 |
Why?
|
Adrenal Cortex Hormones | 1 | 2017 | 1854 | 0.080 |
Why?
|
Calcium | 2 | 2020 | 5755 | 0.080 |
Why?
|
Organizational Objectives | 3 | 2014 | 438 | 0.080 |
Why?
|
Time Factors | 8 | 2022 | 40038 | 0.070 |
Why?
|
Patient Compliance | 1 | 2017 | 2683 | 0.070 |
Why?
|
Occupational Diseases | 1 | 2015 | 1466 | 0.070 |
Why?
|
Patient Selection | 2 | 2013 | 4210 | 0.070 |
Why?
|
Prospective Studies | 7 | 2024 | 53250 | 0.070 |
Why?
|
Adolescent | 9 | 2021 | 85729 | 0.070 |
Why?
|
Louisiana | 1 | 2006 | 108 | 0.070 |
Why?
|
Cardiac Resynchronization Therapy | 1 | 2013 | 531 | 0.070 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2021 | 3921 | 0.070 |
Why?
|
Longitudinal Studies | 3 | 2020 | 13980 | 0.070 |
Why?
|
Internship and Residency | 1 | 2006 | 5787 | 0.070 |
Why?
|
Prognosis | 6 | 2022 | 29052 | 0.070 |
Why?
|
Ultrasonography | 1 | 2019 | 5986 | 0.070 |
Why?
|
Blood Pressure Determination | 2 | 2020 | 633 | 0.070 |
Why?
|
Wounds and Injuries | 1 | 2018 | 2401 | 0.070 |
Why?
|
Uganda | 2 | 2021 | 1237 | 0.070 |
Why?
|
Critical Illness | 1 | 2018 | 2670 | 0.070 |
Why?
|
Sanitation | 2 | 2016 | 93 | 0.070 |
Why?
|
Texas | 1 | 2006 | 390 | 0.070 |
Why?
|
Developing Countries | 2 | 2015 | 2815 | 0.070 |
Why?
|
Acute Disease | 1 | 2016 | 7150 | 0.070 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2010 | 717 | 0.060 |
Why?
|
Research Design | 1 | 2021 | 5983 | 0.060 |
Why?
|
Health Policy | 1 | 2017 | 2662 | 0.060 |
Why?
|
Diagnosis, Differential | 1 | 2020 | 12954 | 0.060 |
Why?
|
Altruism | 1 | 2006 | 204 | 0.060 |
Why?
|
Lung | 2 | 2020 | 9858 | 0.060 |
Why?
|
Narration | 1 | 2006 | 212 | 0.060 |
Why?
|
Age Distribution | 3 | 2015 | 2899 | 0.060 |
Why?
|
Body Mass Index | 1 | 2022 | 12718 | 0.060 |
Why?
|
Malaria | 1 | 2014 | 1239 | 0.060 |
Why?
|
Electronic Health Records | 2 | 2018 | 4467 | 0.060 |
Why?
|
Hospitalization | 5 | 2021 | 10259 | 0.060 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2020 | 2200 | 0.060 |
Why?
|
Apolipoprotein A-I | 1 | 2005 | 281 | 0.060 |
Why?
|
Child | 5 | 2023 | 77637 | 0.060 |
Why?
|
Drug Evaluation | 1 | 2005 | 647 | 0.060 |
Why?
|
Piperazines | 1 | 2014 | 2487 | 0.060 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2007 | 11729 | 0.060 |
Why?
|
Polymorphism, Genetic | 1 | 2014 | 4326 | 0.060 |
Why?
|
Quality of Health Care | 2 | 2016 | 4370 | 0.050 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2007 | 430 | 0.050 |
Why?
|
Alleles | 1 | 2014 | 6934 | 0.050 |
Why?
|
Physician-Patient Relations | 1 | 2016 | 3229 | 0.050 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2017 | 3047 | 0.050 |
Why?
|
Meta-Analysis as Topic | 1 | 2007 | 1340 | 0.050 |
Why?
|
American Dental Association | 1 | 2021 | 17 | 0.050 |
Why?
|
Sex Factors | 3 | 2019 | 10394 | 0.050 |
Why?
|
Heroin | 1 | 2022 | 117 | 0.050 |
Why?
|
Empathy | 1 | 2006 | 474 | 0.050 |
Why?
|
Communication | 1 | 2016 | 3748 | 0.050 |
Why?
|
Health Services Research | 2 | 2020 | 1836 | 0.050 |
Why?
|
Severity of Illness Index | 2 | 2018 | 15526 | 0.050 |
Why?
|
Tuberculosis | 1 | 2014 | 1914 | 0.050 |
Why?
|
Penicillin G Benzathine | 1 | 2020 | 24 | 0.050 |
Why?
|
Monte Carlo Method | 2 | 2017 | 1254 | 0.050 |
Why?
|
Environmental Exposure | 1 | 2015 | 4232 | 0.050 |
Why?
|
Medication Adherence | 3 | 2017 | 2063 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2020 | 10940 | 0.050 |
Why?
|
Renin-Angiotensin System | 1 | 2005 | 758 | 0.050 |
Why?
|
Prisons | 1 | 2022 | 161 | 0.040 |
Why?
|
Kidney Failure, Chronic | 1 | 2012 | 2534 | 0.040 |
Why?
|
Schools, Medical | 1 | 2006 | 879 | 0.040 |
Why?
|
Clinical Competence | 1 | 2015 | 4687 | 0.040 |
Why?
|
Sex Distribution | 2 | 2015 | 2298 | 0.040 |
Why?
|
Heart Transplantation | 1 | 2013 | 3113 | 0.040 |
Why?
|
United States Food and Drug Administration | 1 | 2007 | 1582 | 0.040 |
Why?
|
Accidents, Aviation | 1 | 2018 | 14 | 0.040 |
Why?
|
Colorado | 1 | 2019 | 163 | 0.040 |
Why?
|
Echocardiography | 2 | 2022 | 5096 | 0.040 |
Why?
|
Risk | 2 | 2021 | 9677 | 0.040 |
Why?
|
Florida | 1 | 2020 | 435 | 0.040 |
Why?
|
Wit and Humor as Topic | 1 | 2018 | 31 | 0.040 |
Why?
|
Genetic Testing | 2 | 2022 | 3439 | 0.040 |
Why?
|
Pentoxifylline | 1 | 1999 | 55 | 0.040 |
Why?
|
Poverty | 2 | 2021 | 2660 | 0.040 |
Why?
|
Health Behavior | 2 | 2024 | 2634 | 0.040 |
Why?
|
Hypercalcemia | 1 | 2001 | 409 | 0.040 |
Why?
|
Aircraft | 1 | 2018 | 123 | 0.040 |
Why?
|
Sodium Channel Blockers | 1 | 2019 | 176 | 0.040 |
Why?
|
Phosphodiesterase Inhibitors | 1 | 1999 | 211 | 0.040 |
Why?
|
New York | 1 | 2020 | 885 | 0.040 |
Why?
|
Kenya | 1 | 2020 | 685 | 0.040 |
Why?
|
Obesity | 3 | 2024 | 12744 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 1 | 2020 | 20121 | 0.040 |
Why?
|
Models, Economic | 1 | 2021 | 712 | 0.040 |
Why?
|
Macrophages, Alveolar | 1 | 1999 | 407 | 0.030 |
Why?
|
Probability | 1 | 2021 | 2505 | 0.030 |
Why?
|
Length of Stay | 2 | 2019 | 6311 | 0.030 |
Why?
|
Health Planning Organizations | 1 | 2015 | 12 | 0.030 |
Why?
|
Bioprosthesis | 1 | 2020 | 597 | 0.030 |
Why?
|
Vesico-Ureteral Reflux | 1 | 2019 | 427 | 0.030 |
Why?
|
Injury Severity Score | 1 | 2018 | 1014 | 0.030 |
Why?
|
Delayed-Action Preparations | 1 | 2019 | 967 | 0.030 |
Why?
|
Diagnosis | 1 | 2016 | 154 | 0.030 |
Why?
|
Child, Preschool | 4 | 2021 | 40964 | 0.030 |
Why?
|
Ventricular Remodeling | 1 | 2022 | 1225 | 0.030 |
Why?
|
International Classification of Diseases | 1 | 2020 | 866 | 0.030 |
Why?
|
Reproducibility of Results | 3 | 2020 | 19894 | 0.030 |
Why?
|
Gross Domestic Product | 1 | 2014 | 77 | 0.030 |
Why?
|
Insecticide-Treated Bednets | 1 | 2014 | 64 | 0.030 |
Why?
|
Vasodilator Agents | 1 | 2019 | 974 | 0.030 |
Why?
|
Tuberculosis, Pulmonary | 1 | 2001 | 811 | 0.030 |
Why?
|
Lactic Acid | 1 | 1999 | 1131 | 0.030 |
Why?
|
Survival Rate | 2 | 2022 | 12786 | 0.030 |
Why?
|
Urban Population | 1 | 2022 | 2021 | 0.030 |
Why?
|
Accidents, Traffic | 1 | 2019 | 819 | 0.030 |
Why?
|
Predictive Value of Tests | 2 | 2019 | 15067 | 0.030 |
Why?
|
Ambulatory Care Facilities | 1 | 2020 | 934 | 0.030 |
Why?
|
Databases, Factual | 2 | 2020 | 7729 | 0.030 |
Why?
|
Urinary Bladder | 1 | 2019 | 1173 | 0.030 |
Why?
|
Antitubercular Agents | 1 | 2001 | 1320 | 0.030 |
Why?
|
Health Care Surveys | 1 | 2020 | 2453 | 0.030 |
Why?
|
Infant | 3 | 2021 | 35122 | 0.030 |
Why?
|
Thrombolytic Therapy | 1 | 2022 | 2162 | 0.030 |
Why?
|
Syphilis | 1 | 2014 | 227 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 2 | 2013 | 6539 | 0.030 |
Why?
|
Geriatric Assessment | 1 | 2019 | 1372 | 0.030 |
Why?
|
Animals | 2 | 2019 | 168660 | 0.030 |
Why?
|
Safety | 1 | 2016 | 1184 | 0.030 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 2022 | 1391 | 0.030 |
Why?
|
Focus Groups | 1 | 2016 | 1320 | 0.020 |
Why?
|
Health Priorities | 1 | 2014 | 380 | 0.020 |
Why?
|
Office Visits | 1 | 2015 | 598 | 0.020 |
Why?
|
Linear Models | 1 | 2021 | 5952 | 0.020 |
Why?
|
Socioeconomic Factors | 2 | 2014 | 7784 | 0.020 |
Why?
|
Peripheral Arterial Disease | 1 | 2020 | 1188 | 0.020 |
Why?
|
Liver | 1 | 2005 | 7479 | 0.020 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2019 | 1209 | 0.020 |
Why?
|
Refractory Period, Electrophysiological | 1 | 2008 | 39 | 0.020 |
Why?
|
Life Expectancy | 1 | 2015 | 1184 | 0.020 |
Why?
|
Alcoholism | 1 | 2019 | 1907 | 0.020 |
Why?
|
Chronic Disease | 1 | 2023 | 9139 | 0.020 |
Why?
|
Endovascular Procedures | 1 | 2022 | 1980 | 0.020 |
Why?
|
Disease Progression | 1 | 2005 | 13273 | 0.020 |
Why?
|
Benchmarking | 1 | 2014 | 1042 | 0.020 |
Why?
|
Infant, Newborn | 2 | 2021 | 25609 | 0.020 |
Why?
|
Public Health | 1 | 2021 | 2603 | 0.020 |
Why?
|
Disability Evaluation | 1 | 2015 | 1828 | 0.020 |
Why?
|
Analgesics, Opioid | 1 | 2023 | 3677 | 0.020 |
Why?
|
Massachusetts | 1 | 2020 | 8660 | 0.020 |
Why?
|
Nutritional Status | 1 | 2015 | 1608 | 0.020 |
Why?
|
Single-Blind Method | 1 | 2010 | 1586 | 0.020 |
Why?
|
Propensity Score | 1 | 2013 | 1781 | 0.020 |
Why?
|
Decision Support Systems, Clinical | 1 | 2015 | 1164 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2019 | 12243 | 0.020 |
Why?
|
Diet | 1 | 2024 | 7930 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2016 | 2265 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2018 | 3679 | 0.020 |
Why?
|
Occupational Exposure | 1 | 2015 | 1787 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2019 | 21733 | 0.020 |
Why?
|
Anti-Retroviral Agents | 1 | 2014 | 1714 | 0.020 |
Why?
|
Logistic Models | 1 | 2019 | 13404 | 0.020 |
Why?
|
Cytokines | 1 | 1999 | 7324 | 0.010 |
Why?
|
Kidney | 1 | 2019 | 7185 | 0.010 |
Why?
|
Disease Management | 1 | 2014 | 2459 | 0.010 |
Why?
|
Pulmonary Veins | 1 | 2008 | 761 | 0.010 |
Why?
|
Pregnancy | 2 | 2014 | 29140 | 0.010 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2014 | 2027 | 0.010 |
Why?
|
Action Potentials | 1 | 2008 | 1804 | 0.010 |
Why?
|
Greece | 1 | 2001 | 344 | 0.010 |
Why?
|
Mutation | 1 | 2005 | 29777 | 0.010 |
Why?
|
Respiratory Care Units | 1 | 1999 | 10 | 0.010 |
Why?
|
Survival Analysis | 1 | 2013 | 10251 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2019 | 7658 | 0.010 |
Why?
|
Depression, Chemical | 1 | 1999 | 191 | 0.010 |
Why?
|
Pyruvic Acid | 1 | 1999 | 200 | 0.010 |
Why?
|
Comorbidity | 1 | 2013 | 10380 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2013 | 12354 | 0.010 |
Why?
|
Albumins | 1 | 2001 | 568 | 0.010 |
Why?
|
Physicians | 1 | 2016 | 4569 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2020 | 15281 | 0.010 |
Why?
|
Cell Hypoxia | 1 | 1999 | 675 | 0.010 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 1999 | 768 | 0.010 |
Why?
|
Macrophage Activation | 1 | 1999 | 559 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2010 | 14714 | 0.010 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1999 | 902 | 0.010 |
Why?
|
Interleukin-1 | 1 | 1999 | 1263 | 0.010 |
Why?
|
Leukocytes, Mononuclear | 1 | 1999 | 1836 | 0.010 |
Why?
|
Lipopolysaccharides | 1 | 1999 | 2217 | 0.010 |
Why?
|
Hemodynamics | 1 | 1999 | 4197 | 0.010 |
Why?
|
Interleukin-6 | 1 | 1999 | 3208 | 0.010 |
Why?
|
Protein Binding | 1 | 2001 | 9377 | 0.010 |
Why?
|
Respiration, Artificial | 1 | 1999 | 2568 | 0.010 |
Why?
|
Lung Diseases | 1 | 1999 | 1887 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 1999 | 4422 | 0.000 |
Why?
|
Cells, Cultured | 1 | 1999 | 19232 | 0.000 |
Why?
|